Biotechnology
Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)
CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...
2025-04-21 20:10
3938
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved byChi...
2025-04-21 19:00
3389
Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring
A landmark study recently published in March 2025 by JCO Oncology Advances,
demonstrates the potential ofK-TRACKTM
2025-04-19 19:45
5892
VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
SHANGHAI and BOSTON, April 18, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second out-licensing ...
2025-04-18 08:00
2685
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, i...
2025-04-17 16:07
4971
Brain Navi Begins IPO Counseling with First Securities Inc., Setting the Stage for Global MedTech Expansion
ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. ("
Brain Navi") has officially begun IPO counseling with First Securities Inc.,
marking a strategic step toward accessing the capital markets and advancing its
long-term growth in the surgical robot technology industry.
2025-04-17 12:10
3065
Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
* Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases. SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its relat...
2025-04-17 11:05
3215
Saudi Arabia and France Strengthen Health Cooperation Through Strategic Agreements in Biotech and Digital Health
PARIS, April 17, 2025 /PRNewswire/ -- On the second day of an official visit to France, His Excellency Fahad Abdulrahman AlJalajel, Minister of Health of the Kingdom of Saudi Arabia, held bilateral meetings with senior French officials including Minister for Labour, Health, Solidarity and Familie...
2025-04-17 06:21
3297
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the lat...
2025-04-16 23:30
3277
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results ofziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd....
2025-04-16 09:00
3470
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131 I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substan...
2025-04-16 06:45
2524
Chromatin Bioscience Signs Collaboration Agreement with Astellas
EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a
leader in the design of synthetic promoters and gene control systems, is
pleased to announce a collaboration agreement with Astellas Pharma
2025-04-14 17:00
2815
Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment o...
2025-04-12 17:20
4453
Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved
SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with mod...
2025-04-10 19:23
5145
Angel Yeast Delivers Critical Aid to Myanmar Earthquake Victims, Reinforcing Commitment to Global Humanitarian Efforts
YANGON, Myanmar, April 10, 2025 /PRNewswire/ -- In rapid response to Myanmar's catastrophic 7.9-magnitude earthquake, Angel Yeast Co., Ltd. has mobilized emergency relief supplies through the Myanmar Chinese Chamber of Commerce. This decisive action placesAngel Yeast at the forefront of first res...
2025-04-10 16:24
3135
Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation systemexpected to cover the entire PCR workforce, from sample pre-processing to result analysis. - Designed for 24-hour, seven-days-a-week, unattended, CURECA™ reflects the company's mission to ...
2025-04-09 21:00
3917
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
YANTAI, China, April 9, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented during the ...
2025-04-09 10:07
2727
Thermo Fisher Scientific, NSG BIO Collaborate to Strengthen Singapore's Biotech Startup Ecosystem
The collaboration aims to provide advanced resources and scientific expertise to accelerate innovation and drive sustainable growth SINGAPORE, April 9, 2025 /PRNewswire/ -- Thermo Fisher Scientific Inc, the world leader in serving science, has signed a strategic Memorandum of Understanding with ...
2025-04-09 10:00
3196
Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer
* This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development. * The partnership will advance the development of first-in-class precision therapeutics for multiple cancer ty...
2025-04-08 09:00
2704
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced onApril 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Admini...
2025-04-08 08:00
3602
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 311 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 309 media titles]
2026-02-26 19:57
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
9346
